Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gitlab Inc (GTLB) vs Viatris Inc (VTRS) Price & Performance

Gitlab IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Gitlab Inc vs Viatris Inc — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.2× Gitlab Inc's market cap, and Viatris Inc pays a 2.75% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Viatris Inc for 57 Days on average.

GTLBVTRS
Market Cap
$8.92B$20.03B
Volume
4,716,89314,109,977
Sector
TechnologyHealth
52-Week High
$55.09$18.27
52-Week Low
$19.42$9.74
Typical Hold Time
62 Days57 Days
Enterprise Value
$7.66B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gitlab Inc

GitLab (GTLB) trades at $53.56, up 3.02% with strong technical momentum as it approaches resistance at $54. The stock shows bullish moving average signals despite an overbought RSI. Fundamentally, revenue growth remains robust at 21.3% in Q2 2026 with consistent earnings beats, though profitability metrics like negative net income margin and ROE highlight ongoing challenges. Recent news highlights AI-driven product traction and raised guidance, fueling investor optimism.

Outlook: GitLab's AI integration and sales momentum support upside potential, but high valuation multiples and persistent cash burn pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution and competitive pressures.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GTLB
100% Buy0% Sell
Avg holding period · 62 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Gitlab Inc

GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.

Read more on GTLB →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →